NCT03123965|Unknown
Loading search results
Sponsor study identifier
expanded_access
N/A
1 country
1
Study Start
Not reported
Date not reportedPrimary Completion
Not reported
Date not reportedStudy Completion
Not reported
Date not reportedThis is an expanded access program (EAP) for eligible participants. This program is designed to provide access to glecaprevir/ pibrentasvir prior to approval by the local regulatory agency. Availability will depend on territory eligibility. Participating sites will be added as they apply for and are approved for the EAP. A medical doctor must decide whether the potential benefit outweighs the risk of receiving an investigational therapy based on the individual patient's medical history and program eligibility criteria.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
Not reported
Date not reportedClick on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
April 18, 2017
Actual (reported)April 21, 2017
Actual (reported)Glecaprevir will be administered orally.
Pibrentasvir will be administered orally.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Univ Medical Ctr Ljubljana /ID# 161419
Ljubljana, 1000, Slovenia
AbbVie Inc.
AbbVie
First Submitted
April 18, 2017
First Posted
April 21, 2017
Last Updated
January 18, 2020
Record last verified: 2020-01
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: